Syncom Formulations (India) Ltd Sees Mixed Technical Signals Amid Price Momentum Shift

Price Momentum and Market Performance

On 11 Aug 2026, Syncom Formulations closed at ₹14.40, up from the previous close of ₹13.44, marking a robust daily gain of 7.14%. The stock traded within a range of ₹13.45 to ₹14.98, still below its 52-week high of ₹18.90 but comfortably above the 52-week low of ₹10.21. This recent price surge contrasts with the broader market, as the Sensex showed a marginal decline of 0.12% over the past week, while Syncom outperformed with a 9.42% weekly return.

Year-to-date, the stock has delivered a modest 0.91% return, outperforming the Sensex’s negative 7.84%. However, over the last year, Syncom has underperformed significantly, with a 21.27% decline compared to the Sensex’s 1.65% drop. Longer-term returns remain impressive, with a 10-year gain of 443.40%, substantially outpacing the Sensex’s 182.78% over the same period, highlighting the company’s historical growth potential despite recent volatility.

Technical Trend Shift: From Bearish to Mildly Bearish

The technical trend for Syncom Formulations has shifted from a clearly bearish stance to a mildly bearish one, signalling a tentative improvement in price momentum. This subtle change suggests that while the downtrend may be easing, the stock has yet to establish a definitive bullish trajectory.

Daily moving averages currently indicate a mildly bearish outlook, reflecting that short-term price averages remain below longer-term averages, which often signals caution for traders. The weekly and monthly Moving Average Convergence Divergence (MACD) indicators remain bearish, underscoring persistent downward momentum in medium and long-term frames.

RSI and Bollinger Bands: Divergent Signals

The Relative Strength Index (RSI) on both weekly and monthly charts shows no clear signal, hovering in neutral territory. This suggests that the stock is neither overbought nor oversold, indicating a potential consolidation phase rather than a decisive directional move.

Conversely, Bollinger Bands present a mixed picture: weekly Bollinger Bands are bullish, implying increased volatility with upward price pressure, while monthly Bollinger Bands remain mildly bearish, signalling that longer-term price volatility is still subdued and slightly negative. This divergence highlights the complexity of the current technical landscape for Syncom.

Additional Technical Indicators: KST, Dow Theory, and OBV

The Know Sure Thing (KST) indicator, which measures momentum across multiple timeframes, remains mildly bearish on the weekly chart and bearish on the monthly chart. This suggests that despite short-term improvements, the broader momentum remains subdued.

Dow Theory analysis offers a slightly more optimistic view, with weekly signals turning mildly bullish, indicating potential early signs of an upward trend. However, monthly Dow Theory remains mildly bearish, reinforcing the need for caution among investors.

On-Balance Volume (OBV), a volume-based indicator that can confirm price trends, shows no clear trend on either weekly or monthly charts. This lack of volume confirmation may imply that recent price gains are not yet supported by strong buying interest, which could limit the sustainability of the rally.

Mojo Score and Grade Update

MarketsMOJO assigns Syncom Formulations a Mojo Score of 45.0, reflecting a cautious stance on the stock’s prospects. The Mojo Grade was downgraded from Hold to Sell on 09 Feb 2026, signalling a deterioration in the company’s technical and fundamental outlook. This downgrade aligns with the mixed technical signals and the micro-cap status of the company, which often entails higher volatility and risk.

Investors should weigh these technical signals carefully, considering the stock’s recent outperformance against the Sensex in the short term but acknowledging the longer-term bearish momentum and lack of strong volume support.

Valuation and Sector Context

Operating within the Pharmaceuticals & Biotechnology sector, Syncom Formulations faces sector-specific challenges and opportunities. The sector is known for its sensitivity to regulatory developments, research outcomes, and market competition. Syncom’s current price of ₹14.40 remains well below its 52-week high, suggesting room for recovery if positive catalysts emerge.

However, the micro-cap classification indicates limited market capitalisation and liquidity, which can amplify price swings and complicate technical analysis. Investors should consider these factors alongside the technical indicators when making investment decisions.

Investor Takeaway

Syncom Formulations’ recent price momentum shift from bearish to mildly bearish, combined with a 7.14% daily gain, signals a tentative improvement in market sentiment. However, the persistence of bearish MACD readings, neutral RSI, and lack of volume confirmation through OBV suggest that the rally may lack conviction.

Investors should approach the stock with caution, recognising the mixed technical signals and the downgrade in Mojo Grade to Sell. The stock’s historical outperformance over longer periods offers some encouragement, but near-term risks remain elevated due to the micro-cap nature and sector volatility.

Careful monitoring of moving averages, MACD crossovers, and volume trends will be essential to gauge whether Syncom can sustain its upward momentum or if the bearish trend will reassert itself.

Conclusion

In summary, Syncom Formulations (India) Ltd is at a technical crossroads. While short-term indicators and price action hint at a possible recovery, the broader technical landscape remains cautious. The downgrade to a Sell rating by MarketsMOJO reflects this uncertainty. Investors seeking exposure to the Pharmaceuticals & Biotechnology sector may want to consider alternative opportunities with stronger technical and fundamental profiles.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →